Open access
Open access
Powered by Google Translator Translator

RCTs: Once daily oral relugolix combination therapy vs. placebo in patients with endometriosis-associated pain.

23 Jun, 2022 | 10:30h | UTC

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) – The Lancet

Commentaries:

Relugolix combination therapy for endometriosis pain – The Lancet (free registration required)

Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain – Contemporary OB/GYN

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.